Guangdong Hybribio Biotech Co (SZSE:300639) COGS-to-Revenue : 0.50 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co COGS-to-Revenue?

Guangdong Hybribio Biotech Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥91.0 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥183.1 Mil.

Guangdong Hybribio Biotech Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.50.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Guangdong Hybribio Biotech Co's Gross Margin % for the three months ended in Mar. 2024 was 50.31%.

Guangdong Hybribio Biotech Co COGS-to-Revenue Historical Data

The historical data trend for Guangdong Hybribio Biotech Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangdong Hybribio Biotech Co COGS-to-Revenue Chart

Guangdong Hybribio Biotech Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.19

0.27

0.32

0.31

0.39

Guangdong Hybribio Biotech Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.38	0.31	0.47	0.41	0.50

Guangdong Hybribio Biotech Co COGS-to-Revenue Calculation

Guangdong Hybribio Biotech Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	430.417	/	1104.454
	=	0.39

Guangdong Hybribio Biotech Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	90.991	/	183.101
	=	0.50

Guangdong Hybribio Biotech Co (SZSE:300639) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Guangdong Hybribio Biotech Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	90.991 / 183.101
	=	50.31 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Guangdong Hybribio Biotech Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Guangdong Hybribio Biotech Co (SZSE:300639) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000

Website

http://www.hybribio.cn

Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Guangdong Hybribio Biotech Co (SZSE:300639) Headlines

No Headlines